Second Chances to Improve ESRD Outcomes With a Second-Generation Calcimimetic.
作者信息
Middleton John P, Wolf Myles
机构信息
Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
出版信息
JAMA. 2017 Jan 10;317(2):139-141. doi: 10.1001/jama.2016.18631.
Abstract
摘要
相似文献
1
Second Chances to Improve ESRD Outcomes With a Second-Generation Calcimimetic.使用第二代拟钙剂改善终末期肾病结局的新机遇。
JAMA. 2017 Jan 10;317(2):139-141. doi: 10.1001/jama.2016.18631.
2
[Mechanism of uremic osteodystrophy and prevention of hyperparathyroidism in the uremic patient].[尿毒症性骨营养不良的机制及尿毒症患者甲状旁腺功能亢进的预防]
G Ital Nefrol. 2003 May-Jun;20 Suppl 22:S12-6.
3
Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.钙敏感受体激动剂治疗成人继发性甲状旁腺功能亢进症的疗效比较：系统评价和网络荟萃分析。
Am J Kidney Dis. 2020 Sep;76(3):321-330. doi: 10.1053/j.ajkd.2020.02.439. Epub 2020 May 28.
4
The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.拟钙剂AMG 073作为终末期肾病继发性甲状旁腺功能亢进的潜在治疗方法。
J Am Soc Nephrol. 2003 Mar;14(3):575-83. doi: 10.1097/01.asn.0000050224.03126.ad.
5
Bimaxillary full arch fixed dental implant supported treatment for a patient with renal failure and secondary hyperparathyroidism and osteodystrophy.
J Oral Implantol. 2015 Apr;41(2):e36-43. doi: 10.1563/AAID-JOI-D-13-00188. Epub 2013 Dec 27.
6
The Use of Calcimimetics for the Treatment of Secondary Hyperparathyroidism: A 10 Year Evidence Review.拟钙剂用于治疗继发性甲状旁腺功能亢进：十年证据综述
Semin Dial. 2015 Sep-Oct;28(5):497-507. doi: 10.1111/sdi.12357. Epub 2015 Mar 8.
7
[Calcimimetic drugs in stage 3-5 chronic kidney disease].[拟钙剂在3-5期慢性肾脏病中的应用]
Pol Merkur Lekarski. 2012 Apr;32(190):260-2.
8
[Parenteral calcimimetics for the treatment of secondary hyperparathyroidism.].用于治疗继发性甲状旁腺功能亢进的胃肠外钙敏感受体激动剂。
Clin Calcium. 2017;27(4):567-572.
9
Future role of calcimimetics in end-stage renal disease.拟钙剂在终末期肾病中的未来作用。
Adv Ren Replace Ther. 2002 Jul;9(3):200-8. doi: 10.1053/jarr.2002.34841.
10
Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism.拟钙剂盐酸西那卡塞对继发性甲状旁腺功能亢进患者心血管疾病、骨折及健康相关生活质量的影响。
Kidney Int. 2005 Oct;68(4):1793-800. doi: 10.1111/j.1523-1755.2005.00596.x.
引用本文的文献
1
Real-World Experience of Using Etelcalcetide for Secondary Hyperparathyroidism in Community-Based Hemodialysis Centers in Singapore.在新加坡社区血液透析中心使用依特卡肽治疗继发性甲状旁腺功能亢进的真实世界经验。
Cureus. 2023 Nov 2;15(11):e48186. doi: 10.7759/cureus.48186. eCollection 2023 Nov.
2
New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology.继发性甲状旁腺功能亢进的新情况：依特卡塞。意大利肾脏病学会 CKD-MBD 工作组立场文件。
J Nephrol. 2020 Apr;33(2):211-221. doi: 10.1007/s40620-019-00677-0. Epub 2019 Dec 18.
3
Calcimimetics and Bundled Reimbursement.钙敏感受体激动剂和捆绑式报销。
Am J Kidney Dis. 2019 Mar;73(3):385-390. doi: 10.1053/j.ajkd.2018.11.007. Epub 2019 Jan 3.
4
Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide.继发性甲状旁腺功能亢进的治疗：依特卡肽的临床应用价值
Ther Clin Risk Manag. 2017 Jun 1;13:679-689. doi: 10.2147/TCRM.S108490. eCollection 2017.
本文引用的文献
1
Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.依特立钙对比西那卡塞对继发性甲状旁腺功能亢进行血液透析患者甲状旁腺激素的影响：一项随机临床试验。
JAMA. 2017 Jan 10;317(2):156-164. doi: 10.1001/jama.2016.19468.
2
Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials.依特卡塞特德对比安慰剂对接受血液透析伴继发性甲状旁腺功能亢进患者的甲状旁腺激素的影响：两项随机临床试验。
JAMA. 2017 Jan 10;317(2):146-155. doi: 10.1001/jama.2016.19456.
3
Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial.西那卡塞在美国的经济学评估：EVOLVE试验
Value Health. 2015 Dec;18(8):1079-87. doi: 10.1016/j.jval.2015.08.007. Epub 2015 Oct 9.
4
Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial.西那卡塞、透析液钙浓度与EVOLVE试验中的心血管事件
Hemodial Int. 2016 Jul;20(3):421-31. doi: 10.1111/hdi.12382. Epub 2015 Nov 13.
5
Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.西那卡塞、成纤维细胞生长因子 23 与血液透析患者的心血管疾病：评估盐酸西那卡塞降低心血管事件的疗效（EVOLVE）试验。
Circulation. 2015 Jul 7;132(1):27-39. doi: 10.1161/CIRCULATIONAHA.114.013876. Epub 2015 Jun 9.
6
Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial.西那卡塞对接受血液透析患者骨折事件的影响：EVOLVE试验
J Am Soc Nephrol. 2015 Jun;26(6):1466-75. doi: 10.1681/ASN.2014040414. Epub 2014 Dec 11.
7
Associations of ECG interval prolongations with mortality among ESRD patients evaluated for renal transplantation.接受肾移植评估的终末期肾病（ESRD）患者中心电图间期延长与死亡率的关联。
Ann Transplant. 2014 May 30;19:257-68. doi: 10.12659/AOT.889927.
8
Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease.磷酸盐和成纤维细胞生长因子 23 在心血管疾病中的作用。
Nat Rev Nephrol. 2014 May;10(5):268-78. doi: 10.1038/nrneph.2014.49. Epub 2014 Apr 1.
9
Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.西那卡塞对透析患者心血管疾病的影响。
N Engl J Med. 2012 Dec 27;367(26):2482-94. doi: 10.1056/NEJMoa1205624. Epub 2012 Nov 3.
10
Update on fibroblast growth factor 23 in chronic kidney disease.慢性肾脏病中成纤维细胞生长因子 23 的最新研究进展。
Kidney Int. 2012 Oct;82(7):737-47. doi: 10.1038/ki.2012.176. Epub 2012 May 23.
Zotero 插件